Sugi Predict

Sugi Predict / Compounds / SCHEMBL4538765

SCHEMBL4538765

SCHEMBL4538765

CCOC(=O)c1cnc2cc(Br)ccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 5/20 0.61
▸ ALDH1A1 P00352 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PDGFRB P09619 1/20 0.48
▸ PDGFRA P16234 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ SIRT2 Q8IXJ6 1/20 0.47
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ GAA P10253 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HPGDS O60760 2/20 0.45
▸ HTT P42858 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2205670 0.89 ALDH1A1 (0.52) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL10465995 0.87 MAOB (0.65) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL8001650 0.86 MAOB (0.71) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL2202317 0.84 MAOB (0.66) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL2001821 0.84 HPGDS (0.51) MAOBMAPK1HPGDSHTT
SCHEMBL17447286 0.83 MAOB (0.61) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL5647010 0.83 MAOB (0.61) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL2204650 0.83 MAOB (0.65) MAOBPDGFRBPDGFRAMAPTSIRT2
SCHEMBL4156881 0.83 MAOB (0.61) MAOBALDH1A1SMN1; SMN2PDGFRBPDGFRA
SCHEMBL1285459 0.82 CYP2C19 (0.50) MAOBSMN1; SMN2PDGFRBPDGFRAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858919-B2 HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858919-B2 HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858919-B2 HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
EP-4211131-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES The Regents of the University of California (US) 2023-07-19 — — EP disclosed
WO-2022055926-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-17 — — WO disclosed
US-20220033388-A1 HDAC1,2 Inhibitors REGENACY PHARMACEUTICALS, LLC 2022-02-03 — — US disclosed
EP-3565807-B1 OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL MED MOUNT SINAI (US) 2021-09-22 — — EP disclosed
US-20140249148-A1 SELECTIVE HDAC3 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-09-04 — — US disclosed
US-20140243345-A1 SELECTIVE HDAC3 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-08-28 — — US disclosed
US-20140243345-A1 SELECTIVE HDAC3 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-08-28 — — US disclosed
WO-2014121062-A1 SELECTIVE HDAC3 INHIBITORS ACETYLON PHARMACEUTICALS, INC. (US) 2014-08-07 — — WO disclosed
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-05-08 — — US disclosed
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-05-08 — — US disclosed
WO-2013177253-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-28 — — WO disclosed
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 — — EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 — — US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249148-A1 SELECTIVE HDAC3 INHIBITORS HDAC3, HDAC1, HDAC11 MAOB 4242/4885ALDH1A1 2577/4885SMN1; SMN2 2798/4885
US-20140243345-A1 SELECTIVE HDAC3 INHIBITORS HDAC3, HDAC1, HDAC11 MAOB 4291/4885ALDH1A1 2454/4885SMN1; SMN2 2682/4885
US-11858919-B2 HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 MAOB 2942/4885ALDH1A1 1003/4885SMN1; SMN2 969/4885
US-20220033388-A1 HDAC1,2 Inhibitors HDAC1, HDAC2, HDAC11 MAOB 2942/4885ALDH1A1 1003/4885SMN1; SMN2 969/4885
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 MAOB 1760/4885ALDH1A1 199/4885SMN1; SMN2 4521/4885
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES TNNC1, PYGM, GYS1 MAOB 2953/4885ALDH1A1 3470/4885SMN1; SMN2 4/4885
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS HDAC1, HDAC2, HDAC11 MAOB 3223/4885ALDH1A1 746/4885SMN1; SMN2 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.